VNRX-5024

Investigated by: Basilea Pharmaceutica · National Institute of Allergy and Infectious Diseases (NIAID)

today NCT04314206 · Ph 1

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04314206	Jul → Dec 2020	—	Basilea Pharmaceutica	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VNRX-5024	“This is a 2-part dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-5024.” NCT04314206 ↗
Route	Oral	“Administered Orally” NCT04314206 ↗